2. Search Result
Search Result
Results for "

FABP3

" in MedChemExpress (MCE) Product Catalog:

14

Inhibitors & Agonists

1

Biochemical Assay Reagents

1

Peptides

3

Recombinant Proteins

6

Antibodies

3

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-101903
    BMS-309403
    20+ Cited Publications

    		 FABP Cardiovascular Disease Metabolic Disease
    BMS-309403 is a potent, orally active and selective adipocyte fatty acid binding protein (also known as FABP4, aP2) inhibitor with Kis of <2, 250, and 350 nM for FABP4, FABP3, and FABP5, respectively. BMS-309403 interacts with the fatty-acid-binding pocket within the interior of the protein and competitively inhibits the binding of endogenous fatty acids. BMS-309403 improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells [3].
    BMS-309403
  • HY-101903A
    BMS-309403 sodium
    20+ Cited Publications

    		 FABP Cardiovascular Disease Metabolic Disease
    BMS-309403 sodium is a potent, orally active, and selective adipocyte fatty acid binding protein (also known as FABP4, aP2) inhibitor, with Kis of <2, 250, and 350 nM for FABP4, FABP3, and FABP5, respectively. BMS-309403 sodium interacts with the fatty-acid-binding pocket within the interior of the protein and competitively inhibits the binding of endogenous fatty acids. BMS-309403 sodium improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells [3].
    BMS-309403 sodium
  • HY-148665
    FABP-IN-2

    		FABP Others
    FABP-IN-2 is a novel FABP3 ligand. FABP-IN-2 inhibits FABP3/FABP4 with an IC50 of 1.16 μM and 4.27 μM respectively .
    FABP-IN-2
  • HY-W040255
    1-Palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine

    PGPC

    		 Ferroptosis FABP Caspase Interleukin Related Apoptosis Inflammation/Immunology
    1-Palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine is an oxidized phospholipid. 1-Palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine reduces the viability of HUVECs, increases the levels of ferrous ions and lipid peroxidation, promotes the production of superoxide anions, and decreases the levels of glutathione and GPX4 in cells. 1-Palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine upregulates the mRNA and protein levels of FABP3 in HUVECs, impairs mitochondrial membrane potential, and induces ferroptosis-related changes as well as mitochondrial dysfunction and damage. 1-Palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine activates caspase-11 and promotes the continuous release of IL-1β from macrophages and dendritic cells. 1-Palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine inhibits the proliferation of aortic smooth muscle cells and induces apoptosis in these cells. 1-Palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine is applicable to relevant research on atherosclerosis [3] .
    1-Palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine
  • HY-161702
    RO6806051

    		FABP Inflammation/Immunology
    RO6806051 is a selectivity FABP4 and FABP5 inhibitor with human FABP4 Ki values of 0.011 μM and 0.23 μM, and human FABP5 Ki values of 0.086 μM and 1.17 μM. RO6806051 can be used for the research of inflammation-related diseases [3].
    RO6806051
  • HY-163032
    FABP4-IN-3

    		FABP Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    FABP4-IN-3 (compound C3) is a highly selective FABP4 inhibitor (FABP4 Ki = 25 ± 3 a nM, FABP3 Ki = 15.03 μM) which exhibits a 601-fold selectivity over FABP3. FABP4-IN-3 also shows metabolic stability and potent cellular anti-inflammatory activity, making it promising to get involved in the research of metabolic disease, cardiac dysfunction and inflammation-related disease .
    FABP4-IN-3
  • HY-P4115
    CooP

    		FABP Cancer
    CooP is a linear glioblastoma-targeting nonapeptide. CooP binds to the mammary-derived growth inhibitor/fatty acid binding protein 3 (FABP3) in the glioblastoma cells and its associated vasculature. CooP is used for the targeted delivery of chemotherapy and different nanoparticles .
    CooP
  • HY-RS23414
    Fabp3 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Fabp3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Fabp3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Fabp3 Rat Pre-designed siRNA Set A
    Fabp3 Rat Pre-designed siRNA Set A
  • HY-RS04659
    FABP3 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    FABP3 Human Pre-designed siRNA Set A contains three designed siRNAs for FABP3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    FABP3 Human Pre-designed siRNA Set A
    FABP3 Human Pre-designed siRNA Set A
  • HY-RS16971
    Fabp3 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Fabp3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Fabp3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Fabp3 Mouse Pre-designed siRNA Set A
    Fabp3 Mouse Pre-designed siRNA Set A
  • HY-149953
    FABP4-IN-2

    		FABP Inflammation/Immunology
    FABP4-IN-2 (Compd 10g) is a selective and orally active FABP4 inhibitor with the Ki values of 0.51 μM for FABP4, 33.01 μM for FABP3. FABP4-IN-2 can be used in the research of inflammation-related diseases .
    FABP4-IN-2
  • HY-101903R
    BMS-309403 (Standard)

    		Reference Standards FABP Cardiovascular Disease Metabolic Disease
    BMS-309403 (Standard) is the analytical standard of BMS-309403. This product is intended for research and analytical applications. BMS-309403 is a potent, orally active and selective adipocyte fatty acid binding protein (also known as FABP4, aP2) inhibitor with Kis of <2, 250, and 350 nM for FABP4, FABP3, and FABP5, respectively. BMS-309403 interacts with the fatty-acid-binding pocket within the interior of the protein and competitively inhibits the binding of endogenous fatty acids. BMS-309403 improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells [3].
    BMS-309403 (Standard)
  • HY-101903AR
    BMS-309403 sodium (Standard)

    		Reference Standards FABP Cardiovascular Disease Metabolic Disease
    BMS-309403 (sodium) (Standard) is the analytical standard of BMS-309403 (sodium). This product is intended for research and analytical applications. BMS-309403 sodium is a potent, orally active, and selective adipocyte fatty acid binding protein (also known as FABP4, aP2) inhibitor, with Kis of <2, 250, and 350 nM for FABP4, FABP3, and FABP5, respectively. BMS-309403 sodium interacts with the fatty-acid-binding pocket within the interior of the protein and competitively inhibits the binding of endogenous fatty acids. BMS-309403 sodium improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells [3].
    BMS-309403 sodium (Standard)
  • HY-178471
    FABP4/5-IN-6

    		FABP Interleukin Related Metabolic Disease Inflammation/Immunology
    FABP4/5-IN-6 is an orally active, potent FABP4/5 inhibitor (Ki = 0.41/2.53 μM), showing low selectivity over FABP3 (Ki = 59.72 μM). FABP4/5-IN-6 inhibits the secretion of MCP-1 and IL-6 in Lipopolysaccharides (HY-D1056) (LPS)-induced THP-1 macrophage. FABP4/5-IN-6 exhibits significant anti-inflammatory effects and attenuates LPS-induced liver injury. FABP4/5-IN-6 has low hERG inhibition (LD50 > 2000 mg/kg). FABP4/5-IN-6 can be used for the study of Inflammation-related diseases .
    FABP4/5-IN-6

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: